Intravacc And Mylife Technologies Start Development Of Micro-Needle Vaccination To Break With Limitations Of Injected Vaccines

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bilthoven / Enschede, the Netherlands, February 6, 2014 -- Intravacc, the Institute for Translational Vaccinology based in Bilthoven, and MyLifeTechnologies, a Dutch drug delivery technology company in Enschede, The Netherlands, announced today the start of a cooperation to develop intradermal vaccination technology.

In this cooperation, MyLife Technologies and Intravacc combine their respective know how of micro-needle and vaccine technology. The partners aim to develop a safe micro-needle-patch combination loaded with vaccine. This combination targets specific cells in the skin, so called dendritic cells, that efficiently induce protection against disease. Intradermal delivery of vaccines has multiple advantages over conventional intramuscular administration of vaccines: it is painless, has increased efficacy and induces dose-sparing. Furthermore, it is easy to use and may thus allow self-administration of the vaccine. Finally, it has increased stability obviating the need for cold storage of vaccines, which is specifically important for vaccination in developing countries.

The potential of intradermal vaccination technology may provide a great step forward in the development of safe and effective vaccines.

About MyLife Technologies

MyLife Technologies is a spin-off from the University of Twente, MESA+ Institute for Nanotechnology, The Netherlands. MyLife Technologies develops nano-porous Micro-Needle Arrays (npMNA) for the purpose of intradermal or transdermal drug delivery. The npMNA shall be incorporated into a pharmaceutical patch, allowing for simple self-application by the patient. The npMNA are made of biocompatible ceramic material in a cost-efficient, proprietary process.

About Intravacc

Intravacc (Institute for Translational Vaccinology) operates under the Ministry of Public Health, Welfare and Sport, the Netherlands. Intravacc has an extensive infrastructure for translational vaccine R&D and has proficient knowledge in the field of vaccine development and production. Typical clients of Intravacc are companies, governments and other public institutions.

Media Contacts:

Wilma Witkamp
Communication advisor
Phone: +31 (0)30 274 2941
Mobile: +31 (0) 6 5250 4829

MyLife Technologies
Pieter Jan Vos
Phone: +31 (0)20 689 3753
Mobile: +31 (0) 6 2477 8293

Help employers find you! Check out all the jobs and post your resume.

Back to news